Peptron Obtains US Patent for Parkinson's Disease Treatment Candidate Substance

[Asia Economy Reporter Lee Gwan-joo] Peptron announced on the 17th that it has obtained a U.S. patent for its Parkinson's disease treatment candidate substance 'PT320.'

The newly registered patent is an advancement of the GLP-1 peptide series neurodegenerative disease treatment patent, originally licensed from the U.S. National Institutes of Health (NIH), developed into a form with excellent blood-brain barrier (BBB) permeability, expanding the scope of rights to the entire CNS. Peptron's SmartDepot technology was applied.

Choi Ho-il, CEO of Peptron, said, "There seems to be concerns in the market about the insufficient remaining duration of the existing NIH use patent, but this patent acquisition can alleviate such worries," adding, "Since we succeeded in registration first in the U.S., we expect registrations to follow in major countries worldwide, including Europe."

Peptron is currently conducting a Phase 2 clinical trial in Korea for PT320 applying this patented technology, with final results expected to be announced this year.